{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+emission+tomography%2Fcomputed+tomography+scan&page=24", "query": { "intervention": "Positron emission tomography/computed tomography scan", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 1219, "total_pages": 122, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+emission+tomography%2Fcomputed+tomography+scan&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Positron+emission+tomography%2Fcomputed+tomography+scan&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T09:12:37.242Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01034514", "title": "4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Real-time Position Management system", "type": "DEVICE" }, { "name": "Discovery ST multislice PET/CT scanner", "type": "DEVICE" }, { "name": "Infinia Hawkeye SPECT/CT gamma camera", "type": "DEVICE" }, { "name": "Pinnacle3 treatment planning system", "type": "DEVICE" }, { "name": "SKYLight nuclear camera", "type": "DEVICE" }, { "name": "DTPA", "type": "DRUG" }, { "name": "TECHNETIUM TC 99M MAA", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Billy W. Loo Jr.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2009-12", "completion_date": "2014-06-24", "has_results": false, "last_update_posted_date": "2017-05-08", "last_synced_at": "2026-10-21T09:12:37.242Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01034514" }, { "nct_id": "NCT05636540", "title": "In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Pheochromocytoma", "Paraganglioma" ], "interventions": [ { "name": "[18F]FluorThanatrace ([18F]FTT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Heather Wachtel", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-07-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-21T09:12:37.242Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05636540" }, { "nct_id": "NCT01931709", "title": "FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Male Breast Cancer", "Stage II Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer" ], "interventions": [ { "name": "fludeoxyglucose F 18", "type": "RADIATION" }, { "name": "positron emission tomography", "type": "DEVICE" }, { "name": "dynamic contrast-enhanced magnetic resonance imaging", "type": "DEVICE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DEVICE", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2011-11", "completion_date": "2022-10-26", "has_results": true, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-10-21T09:12:37.242Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01931709" }, { "nct_id": "NCT01390584", "title": "Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Bleomycin", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "PET", "type": "DIAGNOSTIC_TEST" }, { "name": "INRT", "type": "RADIATION" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Procarbazine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "RADIATION" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2013-05-24", "completion_date": "2018-05-18", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-10-21T09:12:37.242Z", "location_count": 2, "location_summary": "Stanford, California • Reading, Pennsylvania", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Reading", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01390584" }, { "nct_id": "NCT01541358", "title": "Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bone Cancer" ], "interventions": [ { "name": "fluorine F 18 sodium fluoride", "type": "RADIATION" }, { "name": "positron emission tomography/computed tomography", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2012-05", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2017-06-14", "last_synced_at": "2026-10-21T09:12:37.242Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01541358" }, { "nct_id": "NCT00833625", "title": "FDG-PET-CT and Biomarkers in Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gastrointestinal Disease", "Esophageal Cancer" ], "interventions": [ { "name": "PET/CT (FDG PET/CT)", "type": "PROCEDURE" }, { "name": "Biomarker Testings", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2009-02", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2016-10-28", "last_synced_at": "2026-10-21T09:12:37.242Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00833625" }, { "nct_id": "NCT02506153", "title": "Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Metastatic Cutaneous Melanoma", "Metastatic Mucosal Melanoma", "Metastatic Non-Cutaneous Melanoma", "Non-Cutaneous Melanoma", "Recurrent Cutaneous Melanoma", "Recurrent Mucosal Melanoma", "Recurrent Non-Cutaneous Melanoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Recombinant Interferon Alfa-2b", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1301, "start_date": "2015-11-10", "completion_date": "2027-01-23", "has_results": true, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-21T09:12:37.242Z", "location_count": 552, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 379 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02506153" }, { "nct_id": "NCT02595879", "title": "Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cervical Adenocarcinoma", "Advanced Cervical Adenosquamous Carcinoma", "Advanced Cervical Squamous Cell Carcinoma", "Advanced Vaginal Adenocarcinoma", "Advanced Vaginal Adenosquamous Carcinoma", "Advanced Vaginal Squamous Cell Carcinoma", "Stage IB2 Cervical Cancer AJCC v6 and v7", "Stage II Cervical Cancer AJCC v7", "Stage II Vaginal Cancer AJCC v6 and v7", "Stage III Vaginal Cancer AJCC v6 and v7", "Stage IIIB Cervical Cancer AJCC v6 and v7", "Stage IVA Cervical Cancer AJCC v6 and v7", "Stage IVA Vaginal Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Brachytherapy", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "High-Dose Rate Brachytherapy", "type": "RADIATION" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Triapine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 21, "start_date": "2019-09-18", "completion_date": "2027-04-29", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-21T09:12:37.242Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Los Angeles, California • Pasadena, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Fairway", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02595879" }, { "nct_id": "NCT05111574", "title": "Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anal Melanoma", "Bladder Melanoma", "Cervical Melanoma", "Esophageal Melanoma", "Gallbladder Melanoma", "Head and Neck Mucosal Melanoma", "Mucosal Melanoma", "Nasopharyngeal Mucosal Melanoma", "Oral Cavity Mucosal Melanoma", "Penile Mucosal Melanoma", "Rectal Melanoma", "Recurrent Mucosal Melanoma", "Sinonasal Mucosal Melanoma", "Urethral Melanoma", "Urinary System Mucosal Melanoma", "Vaginal Melanoma", "Vulvar Melanoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2022-08-11", "completion_date": "2027-07-15", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-21T09:12:37.242Z", "location_count": 142, "location_summary": "Auburn, California • Berkeley, California • Fremont, California + 116 more", "locations": [ { "city": "Auburn", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05111574" }, { "nct_id": "NCT06447103", "title": "An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear Cell Renal Cell Carcinoma", "Sarcomatoid Renal Cell Carcinoma", "Stage II Renal Cell Cancer", "Stage III Renal Cell Cancer", "Stage IV Renal Cell Cancer" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Zirconium Zr 89 Girentuximab", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2024-08-06", "completion_date": "2030-12-01", "has_results": false, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-21T09:12:37.242Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06447103" } ] }